查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046350

人工智慧在癌症診斷領域的市場－全球產業規模、佔有率、趨勢、機會和預測：按技術、癌症類型、最終用戶、地區和競爭格局分類，2021-2031年

Artificial Intelligence In Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Cancer Type, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球癌症診斷人工智慧 (AI) 市場預計將從 2025 年的 1.2911 億美元大幅成長至 2031 年的 2.1439 億美元，複合年成長率為 8.82%。

在這一領域，機器學習演算法和計算模型被用於分析醫學影像和患者數據，以檢測惡性腫瘤。推動這一領域發展的主要因素是全球癌症發生率的上升，這使得人們迫切需要快速、準確的診斷工具來減輕醫療系統的負擔。此外，熟練放射科醫師的嚴重短缺也促使人們尋求能夠改善診斷流程和提高準確性的自動化解決方案。美國癌症協會預測，2025年，美國將新增2,041,910例癌症病例。然而，這些先進技術的廣泛應用面臨著許多挑戰，尤其是嚴格的資料隱私法規以及監管核准所需的複雜檢驗流程。如何在利用龐大資料集訓練演算法的同時保護敏感的患者訊息，是一大難題，這使得將這些工具無縫整合到日常臨床實踐中變得困難重重。

市場概覽
預測期 2027-2031
市場規模：2025年 1.2911億美元
市場規模：2031年 2.1439億美元
複合年成長率：2026-2031年 8.82%
成長最快的細分市場 結腸癌
最大的市場 北美洲

市場促進因素

政府的措施和資金投入是推動市場發展的主要動力，世界各地的公共衛生機構都在大力投資人工智慧（AI），以應對日益沉重的癌症治療負擔。各國政府資助的研究旨在利用計算模型更早、更準確地檢測癌症，進而降低長期醫療成本。這種資金支持正在加速人工智慧演算法從實驗階段向臨床應用的過渡，同時也鼓勵私部門的參與。例如，根據美國國立衛生研究院（NIH）的報告，美國衛生與公眾服務部於2025年9月宣布，將兒童癌症數據舉措的資金增加一倍，達到1億美元，以促進人工智慧驅動的診斷項目和數據分析。深度學習和電腦視覺技術的進步透過顯著提高醫學影像分析的準確性，進一步推動了市場擴張。這些創新使軟體能夠識別人眼可能忽略的放射影像中的細微模式，從而顯著減少診斷錯誤並加快檢測結果的交付。這些進步正在迅速增強監管機構的信心，並為這些工具的商業化和部署創造有利環境。 2025年3月，《矽谷評論》（The Silicon Review）報道稱，美國食品藥物管理局（FDA）核准了HealthAI公司的深度學習診斷工具，該工具利用即時影像數據以極高的準確率檢測早期癌症。此外，2025年7月，《醫療未來學家》（The Medical Futurist）指出，FDA核准的AI醫療設備累積數量已達1,250種，凸顯了這些技術與現代診斷流程的深度融合。

市場挑戰

全球癌症診斷人工智慧市場的發展面臨諸多阻礙，主要原因是嚴格的資料隱私法規以及監管核准所需的複雜檢驗程序。開發精準的診斷演算法需要存取大量高度敏感的醫學影像資料集，但遵守 HIPAA 和 GDPR 等有關病患隱私的法律體制卻帶來了巨大的營運挑戰。這種對海量資料存取的需求與嚴格保護隱私的義務之間的固有矛盾，推高了開發成本，延長了新產品的上市時間，並最終阻礙了創新步伐。此外，監管機構為確保演算法安全性和資料安全而進行的嚴格審查也成為商業化的瓶頸。醫療機構往往只有在完全確信合規性和問責制的情況下才會考慮採用此類工具，這限制了製造商的潛在市場。這種擔憂直接影響了採用率，並阻礙了產生收入。根據美國醫學會 (AMA) 2024 年的一項調查，87% 的醫生將資料隱私保障列為採用人工智慧工具的首要標準。因此，獲得監管部門批准和實現隱私合規的難度仍然是阻礙市場成長軌蹟的主要障礙。

市場趨勢

人工智慧驅動的液態生物檢體分析的引入，透過檢測循環生物標記實現非侵入性腫瘤監測，正在革新腫瘤學領域。與侵入性組織切片檢查相比，人工智慧演算法現在能夠以高靈敏度解碼循環腫瘤DNA和外泌體的複雜模式，從而加速微量殘存疾病的早期檢測。這項技術已被證明對於識別傳統方法常常忽略的抗藥性機制至關重要，並透過及時干預改善患者預後。 2025年12月，News-Medical.Net報導了一篇題為「人工智慧輔助液態生物檢體在癌症早期檢測中展現前景」的報告。該報告整合了100多項最新研究，證實人工智慧驅動的外泌體分析已發展到足以成為快速識別惡性腫瘤的實用臨床工具。同時，向基於雲端的人工智慧診斷平台的明顯轉變正在重塑市場基礎設施​​，使醫療系統能夠在無需承擔高昂的本地硬體成本的情況下部署先進的演算法。這一轉變簡化了海量多模態資料集的聚合，這些資料集對於訓練和運行基礎模型至關重要，從而使高效能診斷工具的獲取更加普及，尤其是在資源受限的環境中。雲端架構也支援即時人工智慧更新，並能無縫整合到地理位置分散的現有臨床工作流程。根據Google 報導3月發布的博文《人工智慧推動醫學和科學發現》，阿波羅放射國際公司宣布計劃利用基於雲端的人工智慧模式進行300萬次免費肺癌和乳癌篩檢，這充分展現了這種部署方式的巨大擴充性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：人工智慧在癌症診斷領域的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按技術（軟體解決方案、硬體、服務）
    • 癌症類型（乳癌、肺癌、攝護腺癌、大腸癌、腦瘤、其他）
    • 按最終使用者（醫院、手術中心和醫療機構等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美癌症診斷人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲癌症診斷人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區人工智慧在癌症診斷領域的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲癌症診斷人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：人工智慧在南美癌症診斷領域的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球癌症診斷人工智慧市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Medial EarlySign Ltd
  • Cancer Center Sp. z oo
  • Microsoft Corporation
  • Flatiron Health Inc.
  • PathAI Inc.
  • Therapixel SA
  • Tempus Labs, Inc.
  • Paige AI, Inc.
  • Kheiron Medical Technologies Limited
  • SkinVision BV

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16238

The global market for Artificial Intelligence in Cancer Diagnostics is projected to expand significantly, rising from USD 129.11 Million in 2025 to USD 214.39 Million by 2031, demonstrating an 8.82% compound annual growth rate. This sector leverages machine learning algorithms and computational models to analyze medical images and patient data for malignancy detection. Growth is primarily fueled by the increasing worldwide incidence of cancer, which creates an urgent need for swift and accurate diagnostic tools to ease burdens on healthcare systems. Moreover, a critical shortage of skilled radiologists intensifies the demand for automated solutions that can enhance diagnostic workflows and precision. The American Cancer Society projected 2,041,910 new cancer cases in the United States for 2025.However, widespread adoption of these advanced technologies encounters substantial challenges, notably stringent data privacy regulations and the intricate validation processes mandated for regulatory approval. Safeguarding sensitive patient information while simultaneously utilizing vast datasets for algorithm training presents a formidable hurdle, complicating the seamless integration of these tools into routine clinical practice.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 129.11 Million
Market Size 2031USD 214.39 Million
CAGR 2026-20318.82%
Fastest Growing SegmentColorectal Cancer
Largest MarketNorth America

Market Driver

Government initiatives and funding represent a primary driver for the market, as public health organizations globally commit significant investments in artificial intelligence to combat the escalating burden of oncology. Governments are directing capital into research aimed at utilizing computational models for earlier and more precise cancer detection, thereby seeking to reduce long-term healthcare expenditures. This financial backing accelerates the transition of AI algorithms from experimental development into clinical application and encourages participation from the private sector. For instance, in September 2025, the U.S. Department of Health and Human Services, as reported by the National Institutes of Health, announced a doubling of funding for the Childhood Cancer Data Initiative to $100 million, specifically to advance AI-based diagnostic projects and data analysis.Technological advancements in deep learning and computer vision further fuel market expansion by significantly improving the precision of medical imaging analysis. These innovations empower software to identify subtle patterns in radiology scans that human observation might miss, leading to substantial reductions in diagnostic errors and quicker turnaround times. Such progress is rapidly building regulatory confidence, fostering a favorable environment for the commercialization and adoption of these tools. The Silicon Review reported in March 2025 that the U.S. Food and Drug Administration approved HealthAI's deep learning diagnostic tool, which uses real-time imaging data for highly precise early-stage cancer detection. Furthermore, The Medical Futurist noted in July 2025 that the cumulative number of FDA-authorized AI-enabled medical devices had reached 1,250, underscoring the deep integration of these technologies into modern diagnostic workflows.

Market Challenge

The growth of the Global Artificial Intelligence in Cancer Diagnostics Market faces significant constraints due to stringent data privacy regulations and the complex validation procedures required for regulatory approval. Developing accurate diagnostic algorithms necessitates access to extensive datasets of sensitive medical imagery; however, navigating legal frameworks like HIPAA and GDPR concerning patient confidentiality creates considerable operational challenges. This inherent conflict between the need for vast data access and the mandate for strict privacy protection elevates development costs and prolongs the time required to introduce new products to market, thereby impeding the pace of innovation.Furthermore, the rigorous scrutiny applied by regulatory bodies to guarantee algorithm safety and data security acts as a bottleneck for commercialization. Healthcare providers often hesitate to adopt these tools without absolute certainty regarding compliance and liability, which consequently restricts the addressable market for manufacturers. This apprehension directly impacts adoption rates and hinders revenue generation. According to the American Medical Association in 2024, 87% of physicians cited data privacy assurances as a primary criterion for adopting AI tools. Consequently, the challenging path to regulatory clearance and privacy compliance remains a principal impediment to the market's growth trajectory.

Market Trends

The adoption of AI-enhanced liquid biopsy analysis is revolutionizing oncology by enabling non-invasive tumor monitoring through the examination of circulating biomarkers. In contrast to invasive tissue biopsies, AI algorithms can now decipher complex patterns in circulating tumor DNA and exosomes with high sensitivity, facilitating earlier detection of minimal residual disease. This technology is proving crucial for identifying resistance mechanisms often overlooked by traditional methods, thereby improving patient outcomes through timely intervention. News-Medical.Net reported in December 2025 that the 'AI-assisted liquid biopsies show promise for early cancer detection' report, synthesizing over 100 recent studies, confirmed the sufficient advancement of AI-driven exosome analysis to become a viable clinical tool for rapid malignancy identification.Concurrently, a distinct shift towards cloud-based AI diagnostic platforms is reconfiguring the market infrastructure, allowing healthcare systems to implement sophisticated algorithms without incurring prohibitive on-premise hardware expenses. This transition streamlines the aggregation of massive, multi-modal datasets essential for training and operating foundation models, thereby democratizing access to high-performance diagnostic tools, particularly in resource-limited settings. Cloud architectures also support real-time updates and seamless integration of AI into existing clinical workflows across geographically dispersed locations. According to a Google Blog update in March 2025 titled 'Advancing healthcare and scientific discovery with AI', Apollo Radiology International announced its plan to use cloud-based AI models to provide 3 million free screenings for lung and breast cancer, showcasing the immense scalability of this deployment approach.

Key Market Players

  • Medial EarlySign Ltd
  • Cancer Center Sp. z o.o.
  • Microsoft Corporation
  • Flatiron Health Inc.
  • PathAI Inc.
  • Therapixel SA
  • Tempus Labs, Inc.
  • Paige AI, Inc.
  • Kheiron Medical Technologies Limited
  • SkinVision B.V.

Report Scope

In this report, the Global Artificial Intelligence In Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Intelligence In Cancer Diagnostics Market, By Technology

  • Software Solutions
  • Hardware
  • Services

Artificial Intelligence In Cancer Diagnostics Market, By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Others

Artificial Intelligence In Cancer Diagnostics Market, By End-User

  • Hospital
  • Surgical Centers and Medical Institutes
  • Others

Artificial Intelligence In Cancer Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence In Cancer Diagnostics Market.

Available Customizations:

Global Artificial Intelligence In Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Software Solutions, Hardware, Services)
    • 5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
    • 5.2.3. By End-User (Hospital, Surgical Centers and Medical Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Cancer Type
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By End-User

7. Europe Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Cancer Type
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By End-User

8. Asia Pacific Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Cancer Type
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Cancer Type
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By End-User

10. South America Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Cancer Type
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Artificial Intelligence In Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Medial EarlySign Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cancer Center Sp. z o.o.
  • 15.3. Microsoft Corporation
  • 15.4. Flatiron Health Inc.
  • 15.5. PathAI Inc.
  • 15.6. Therapixel SA
  • 15.7. Tempus Labs, Inc.
  • 15.8. Paige AI, Inc.
  • 15.9. Kheiron Medical Technologies Limited
  • 15.10. SkinVision B.V.

16. Strategic Recommendations

17. About Us & Disclaimer